The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Open accessAbstract
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. METHODS: We conducted a three-part, phase 3 trial in which patients 12 years of age or older underwent randomization in a 1:1 ratio to receive subcutaneous dupilumab at a weekly dose of 300 mg or placebo (Part A) or in a 1:1:1 ratio to receive 300 mg of dupilumab either weekly or every 2 weeks or weekly placebo (Part B) up to week 24. Eligible patients who completed Part A or Part B continued the trial in Part C, in which those who completed Part A received dupilumab at a weekly dose of 300 mg up to week 52 (the Part A-C group); Part C that included the eligible patients from Part B is ongoing. The two primary end points at week 24 were histologic remission (≤6 eosinophils per high-power field) and the change from baseline in the Dysphagia Symptom Questionnaire (DSQ) score (range, 0 to 84, with higher values indicating more frequent or more severe dysphagia). RESULTS: In Part A, histologic remission occurred in 25 of 42 patients (60%) who received weekly dupilumab and in 2 of 39 patients (5%) who received placebo (difference, 55 percentage points; 95% confidence interval [CI], 40 to 71; P<0.001). In Part B, histologic remission occurred in 47 of 80 patients (59%) with weekly dupilumab, in 49 of 81 patients (60%) with dupilumab every 2 weeks, and in 5 of 79 patients (6%) with placebo (difference between weekly dupilumab and placebo, 54 percentage points; 95% CI, 41 to 66 [P<0.001]; difference between dupilumab every 2 weeks and placebo, 56 percentage points; 95% CI, 43 to 69 [not significant per hierarchical testing]). The mean (±SD) DSQ scores at baseline were 33.6±12.41 in Part A and 36.7±11.22 in Part B; the scores improved with weekly dupilumab as compared with placebo, with differences of -12.32 (95% CI, -19.11 to -5.54) in Part A and -9.92 (95% CI, -14.81 to -5.02) in Part B (both P<0.001) but not with dupilumab every 2 weeks (difference in Part B, -0.51; 95% CI, -5.42 to 4.41). Serious adverse events occurred in 9 patients during the Part A or B treatment period (in 7 who received weekly dupilumab, 1 who received dupilumab every 2 weeks, and 1 who received placebo) and in 1 patient in the Part A-C group during the Part C treatment period who received placebo in Part A and weekly dupilumab in Part C. CONCLUSIONS: Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lucendo, A. J., Molina‐Infante, J., Arias, Á., von Arnim, U., Bredenoord, A. J., Bussmann, C., Amil Dias, J., Bove, M., González‐Cervera, J., Larsson, H., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640616689525 · Cited by 1,075
Self-citationHirano, I., Moy, N., Heckman, M. G., Thomas, C. S., Gonsalves, N., & Achem, S. R. (2013) · Gut · doi:10.1136/gutjnl-2011-301817 · Cited by 945
Self-citationEpidemiology and Natural History of Eosinophilic Esophagitis
Dellon, E. S., & Hirano, I. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.067 · Cited by 781
Self-citationFuruta, G. T., & Katzka, D. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1502863 · Cited by 549
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Self-citationPathophysiology of Eosinophilic Esophagitis
O’Shea, K. M., Aceves, S. S., Dellon, E. S., Gupta, S. K., Spergel, J. M., Furuta, G. T., & Rothenberg, M. E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.065 · Cited by 502
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Hirano, I., Dellon, E. S., Hamilton, J. D., Collins, M. H., Peterson, K., Chehade, M., Schoepfer, A. M., Safroneeva, E., Rothenberg, M. E., Falk, G. W., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.042 · Cited by 460
Self-citationMurphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Self-citationCollins, M. H., Martin, L. J., Alexander, E. S., Boyd, J. T., Sheridan, R., He, H., Pentiuk, S., Putnam, P. E., Abonia, J. P., Mukkada, V. A., et al. (2016) · Diseases of the Esophagus · doi:10.1111/dote.12470 · Cited by 402
Self-citation
Cited by
Gravel, J., D’Amours-Gravel, M., & Osmanlliu, E. (2023) · Mayo Clinic Proceedings: Digital Health · doi:10.1016/j.mcpdig.2023.05.004 · Cited by 222
Gravel, J., D’Amours-Gravel, M., & Osmanlliu, E. (2023) · doi:10.1101/2023.03.16.23286914 · Cited by 220
Neuroimmune mechanisms of type 2 inflammation in the skin and lung
Tamari, M., & Ver Heul, A. M. (2025) · Allergology International · doi:10.1016/j.alit.2025.02.001 · Cited by 17
Metadata
- Authors
- Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., Kosloski, M. P., Kamal, M. A., Hamilton, J. D., Beazley, B., McCann, E., Patel, K., Mannent, L. P., Laws, E., Akinlade, B., Amin, N., Lim, W. K., Wipperman, M. F., Ruddy, M., Patel, N., Weinreich, D. R., Yancopoulos, G. D., Shumel, B., Maloney, J., Giannelou, A., & Shabbir, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-22
- Volume
- 387
- Issue
- 25
- Pages
- 2317-2330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4313237193
- Cited by
- 484
- References
- 24
- FWCI
- 82.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. https://app.cochat.ai/papers/10.1056/nejmoa2205982
- The paper
- Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., Kosloski, M. P., Kamal, M. A., Hamilton, J. D., Beazley, B., McCann, E., Patel, K., Mannent, L. P., Laws, E., Akinlade, B., . . . Shabbir, A. (2022). Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2205982
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.